What's new in the medical management of pediatric epilepsy?

Research output: Contribution to journalArticle

Abstract

Epilepsy affects approximately 45 per 100,000 children per year. While many cases respond favorably to antiepileptic therapy, approximately 20% will prove to be medically intractable. This paper reviews some of the recently identified important metabolic and autoimmune etiologies for which there are specific therapies. Additionally, newer antiepileptic medications, including rufinamide, lacosamide, retigabine, eslicarbazepine and brivaracetam and newer dietary options, including the modified Atkins diet and low-glycemic index diet are discussed.

Original languageEnglish (US)
JournalCanadian Journal of Neurological Sciences
Volume39
Issue number6 SUPPL.6
StatePublished - Nov 2012

Fingerprint

Anticonvulsants
Epilepsy
Carbohydrate-Restricted Diet
Pediatrics
Glycemic Index
Diet
Therapeutics
lacosamide
rufinamide
2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide
ezogabine
eslicarbazepine

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

What's new in the medical management of pediatric epilepsy? / Wirrell, Elaine C.

In: Canadian Journal of Neurological Sciences, Vol. 39, No. 6 SUPPL.6, 11.2012.

Research output: Contribution to journalArticle

@article{7fefbfd6a7d04dacaaf6bfc25920c8cf,
title = "What's new in the medical management of pediatric epilepsy?",
abstract = "Epilepsy affects approximately 45 per 100,000 children per year. While many cases respond favorably to antiepileptic therapy, approximately 20{\%} will prove to be medically intractable. This paper reviews some of the recently identified important metabolic and autoimmune etiologies for which there are specific therapies. Additionally, newer antiepileptic medications, including rufinamide, lacosamide, retigabine, eslicarbazepine and brivaracetam and newer dietary options, including the modified Atkins diet and low-glycemic index diet are discussed.",
author = "Wirrell, {Elaine C}",
year = "2012",
month = "11",
language = "English (US)",
volume = "39",
journal = "Canadian Journal of Neurological Sciences",
issn = "0317-1671",
publisher = "Canadian Journal of Neurological Sciences",
number = "6 SUPPL.6",

}

TY - JOUR

T1 - What's new in the medical management of pediatric epilepsy?

AU - Wirrell, Elaine C

PY - 2012/11

Y1 - 2012/11

N2 - Epilepsy affects approximately 45 per 100,000 children per year. While many cases respond favorably to antiepileptic therapy, approximately 20% will prove to be medically intractable. This paper reviews some of the recently identified important metabolic and autoimmune etiologies for which there are specific therapies. Additionally, newer antiepileptic medications, including rufinamide, lacosamide, retigabine, eslicarbazepine and brivaracetam and newer dietary options, including the modified Atkins diet and low-glycemic index diet are discussed.

AB - Epilepsy affects approximately 45 per 100,000 children per year. While many cases respond favorably to antiepileptic therapy, approximately 20% will prove to be medically intractable. This paper reviews some of the recently identified important metabolic and autoimmune etiologies for which there are specific therapies. Additionally, newer antiepileptic medications, including rufinamide, lacosamide, retigabine, eslicarbazepine and brivaracetam and newer dietary options, including the modified Atkins diet and low-glycemic index diet are discussed.

UR - http://www.scopus.com/inward/record.url?scp=84879913737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879913737&partnerID=8YFLogxK

M3 - Article

VL - 39

JO - Canadian Journal of Neurological Sciences

JF - Canadian Journal of Neurological Sciences

SN - 0317-1671

IS - 6 SUPPL.6

ER -